98995-40-5 Usage
General Description
4-Isopropoxybenzenesulfonyl chloride is a chemical compound that is commonly used in organic synthesis and medicinal chemistry as a reagent for the introduction of the sulfonyl chloride functional group. It is a colorless to light yellow liquid with a pungent odor, and is highly reactive, especially with nucleophiles. It is often used in the preparation of sulfonamides, which have a wide range of pharmaceutical applications. Additionally, 4-isopropoxybenzenesulfonyl chloride can also be used as a protecting group for alcohols and amines in organic synthesis. Due to its reactivity and potential hazards, it should be handled and used with caution in a controlled laboratory setting.
Check Digit Verification of cas no
The CAS Registry Mumber 98995-40-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,8,9,9 and 5 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 98995-40:
(7*9)+(6*8)+(5*9)+(4*9)+(3*5)+(2*4)+(1*0)=215
215 % 10 = 5
So 98995-40-5 is a valid CAS Registry Number.
InChI:InChI=1/C9H11ClO3S/c1-7(2)13-8-3-5-9(6-4-8)14(10,11)12/h3-7H,1-2H3
98995-40-5Relevant articles and documents
Design and bio-evaluation of indole derivatives as potent Kv1.5 inhibitors
Guo, Xiaoke,Yang, Qian,Xu, Jing,Zhang, Li,Chu, Hongxi,Yu, Peng,Zhu, Yingying,Wei, Jinglian,Chen, Weilin,Zhang, Yaozhong,Zhang, Xiaojin,Sun, Haopeng,Tang, Yiqun,You, Qidong
, p. 6466 - 6476 (2013/10/22)
Atrial fibrillation (AF) is one of the common arrhythmias that threaten human health. Kv1.5 potassium channel is reported as an efficacious and safe target for the treatment of AF. In this paper, we designed and synthesized three series of compounds through modifying the lead compound RH01617 that was screened out by the pharmacophore model we reported earlier. All of the compounds were evaluated by the whole-patch lamp technology and most of them possessed potent inhibitory activities against Kv1.5. Compounds IIIi and IIIl were evaluated for the target selectivity as well as the pharmacodynamic effects in an isolated rat model. Due to the promising pharmacological behavior, compound IIIl deserves further pharmacodynamic and pharmacokinetic evaluations.
